

## The Relationship between Serum Leptin Level and Bone Mineral Density in Postmenopausal Osteoporotic Women

\* Fahmy Emam; \* Sobhia Ali Mahmoud; \*\* Amany Mohammed El-Said \*\* Mona Mokhatr El-Metwally

\* Physical Medicine, Rheumatology and Rehabilitation,

\*\* Clinical Pathology ,Faculty of medicine for girls, Al-Azhar University

### Abstract :

Postmenopausal osteoporosis is a heterogeneous disorder characterized by a progressive loss of bone tissue that begins after menopause and leads to fracture within 15-20 years from the cessation of the ovarian function. Human leptin is a protein of 167 amino acids. It is manufactured primarily in the adipocytes of white adipose tissue, and the level of circulating leptin is proportional to the total amount of fat in the body. Leptin's effects on bone are mediated via a central neuroendocrine signaling pathway, as well as directly on bone marrow stem cells to enhance their differentiation to osteoblasts and inhibit their differentiation to adipocytes.

**Aim of the Study:** to detect the relation between serum leptin level, total lipid profile and bone mineral density in postmenopausal osteoporotic women.

**Subjects and Methods:** The study was carried on 40 postmenopausal females. According to Dual Energy X-ray absorptiometry (DEXA), the subjects were divided into group A, Tt-score  $\leq$ -2.5, group B, t-score  $<$ -1, leptin and lipid profile were measured for all subjects.

**Conclusion:** The current study has provided evidence that bone mineral density is influenced by serum leptin level in postmenopausal osteoporotic women and positive correlation between serum leptin level and bone mineral density was found.

**Recommendation:** Serum leptin level measurement could be used as a simple and non invasive method for screening programs for osteoporosis in postmenopausal women but the accuracy of this test still needs furtherer studies.

**Abbreviation:** Ob gene : Obese gene; BMD : Bone Mineral Density;

NOF: National Osteoporosis Foundation; M-CSF : Monocyte colony stimulating factor;

BMI: Body mass index; DEXA: Dual-energy X-ray absorptiometry

**Key words:** serum leptin, Bone Mineral Density, Postmenopausal Osteoporotic Women

### Introduction

World Health Organization defined osteoporosis as having a Bone Mineral Density (BMD) that is 2.5 standard deviations below peak bone mineral density<sup>(1)</sup>.

Osteoporosis affects over 200 million people worldwide including 40% of women aged 50 years and over, and 65% of women aged 70 years and over **Kanis et al.**<sup>(2)</sup>

Among the hormones involved in bone and mineral metabolism, leptin has become a subject of considerable interest. Leptin has been reported to have bone anabolic, anti-resorptive, and anti-osteoclastogenic effects<sup>(3)</sup>.

Leptin is a circulating neurohormone produced primarily by adipose tissue as the product of the obese (ob) gene<sup>(4)</sup>. In addition to white adipose tissue, it can also be produced by brown adipose tissue, placenta (syncytiotrophoblasts), ovaries, skeletal muscle, stomach (the lower part of the fundic glands), mammary epithelial cells, bone marrow and liver cells<sup>(5)</sup> (**Margetic et al.**).

Leptin interacts with several types of receptors (Ob-Ra-Ob-Rf, or LepRa-LepRf) that in turn

are encoded by a single gene, Ob-Rb is the only receptor isoform that can signal intracellularly via the JAK state and MAPK signal transduction pathways and is present in hypothalamic nuclei<sup>(6)</sup>. Leptin can also act directly on bone marrow stem cells to enhance their differentiation to osteoblasts and inhibit their differentiation to adipocytes<sup>(7)</sup>

**Shoshana et al.** Postmenopausal Osteoporosis is something that most women are concerned about. The rate at which bone regeneration takes place slows down with age. The rate of regeneration decreases even more after a women goes through menopause. Therefore, women are more susceptible to osteoporosis after menopause<sup>(8)</sup> (**Admi, et al.**). Estrogen acts on estrogen receptor- $\alpha$  (ER $\alpha$ ) and receptor- $\beta$  (ER $\beta$ ) which has high affinity towards osteoblasts and osteoclasts<sup>(9)</sup> (**Manolagas et al.**). Two Primary Mechanisms Promote Increased Osteoclastogenesis and Bone Resorption in the Absence of Estrogen. Under estrogen-deficient conditions, T cells produce elevated levels of

proinflammatory cytokines including TNF-alpha, IL-1, and IL-6. These cytokines promote increased RANK L expression on osteoblasts and stromal cells, which leads to osteoclast differentiation in the presence of M-CSF<sup>(10)</sup>.

**Subjects and Methods:**

**Patients:**

This study included 40 postmenopausal females collected from the Outpatient Clinic of Rheumatology and Rehabilitation at Alzahraa hospital and Sayed Galal hospital during the period from October 2011 to August 2012.

Informed consent was obtained from all participants.

Patients were divided according to their Dual- Energy X-Ray Absorptiometry (DEXA) T- score into two groups:

- 1-Group A (cases): includes 30 post menopausal females with T- score at lumbar spine and neck of the femure below -2.5 .
- 2-Group B (controls):10 postmenopausal females with T- score at lumbar spine and neck of the femure above -1.

**Inclusion criteria:**

-Postmenopausal femals above 50 years old.

**Exclusion criteria:**

- 1- Patients with established medical conditions known to alter BMD and which may cause secondary osteoporosis e.g. hyperthyroidism; hyperparathyroidism, chronic renal insufficiency; chronic liver disease and malignancy.
- 2- Patients receiving drugs for treatment of osteoporosis in the previous 6 months, like bisphosphonates, hormone-replacement therapy (HRT), calcium, vitamin D, calcitonin.
- 3- Patients taking drugs that are known to affect bone metabolism e.g. glucocorticoids,

heparin, anticonvulsants, diuretics and cytotoxics..

**Methods:**

Each participant have been subjected to;

- 1- Full history taking.
- 2- Full physical examination including: body weight, body height .
- 3- Bone densitometry (using DEXA scan).
- 4- Laboratory investigation including serum leptin level and total lipid profile including serum total cholesterol, serum triglycerides,serum low denisty lipoprotein and serum high denisty lipoprotein.

**1-Full history taking**

**2-Full physical examination** including: body weight, body height and body mass index was calculated according to the equation:

$$BMI = \frac{WEIGHT(kg)}{Height(m)^2}$$

**3-Bone densitometry (using DEXA scan)**

Two areas of the skeleton were tested; the lumbar spine and the hip.

**Plasma leptin concentration**

Plasma leptin concentration was determined by using the DAI Leptin enzyme-linked immunosorbent assay (ELISA) solid phase enzyme emmunosorbent asseay based on sandwich supplied by [DRG international in company Int. U.S.A] EIA/2395.

**Total serum lipid profile.**

Total cholesterol (TC), low density lipoprotein (LDL), high density lipoprotein (HDL) cholesterol in the serum samples of the subjects were measured by immunoassay (ELISA).

**Results**

The age of the cases in our study was ranging between (50- 70) years with mean ( 57.3± 13.2) years, and the age of the controls ranging between ( 50-69 ) years with mean (61±15.2) years as shown in (table 1).

**Table (1): Descriptive data of our studied groups are demonstrated in table (1).**

Parameter	cases		Control	
	Mean	Std. Deviation	Mean	Std. Deviation
Age	57.3	13.2	61.2	15.2
Age of Menopause	48.2	227.1	52	12.4
Duration menopause	10	5.21846	6.56	5.20502
BMI	31.065	4.9 6065	29.554	4.650

**Table (2): Comparstion between cases control as regad**

parameter	Cases	controls	p-value
Lumbar T-score	(-3.17±0.71)	0.31 ±0.81	p < 0.01(HS)
Neck of the femure T-score	-2.65±0.76	0.28 ±0.79	p < 0.01

**Table (3): Comparison of biochemical marks between cases and control**

parameter	Cases	controls	p-value
Serum leptin	44.73±11.29	75.35±15.68	p < 0.05(S)
Serum cholesterol	208.6±30.6	166.8±41.6	p < 0.05
Serum LDL	141.5±35.9	88±22.2	p < 0.05
Serum HDL	40.20±8.1	28.90±5.9	p < 0.05
Serum TG	130±80.8	166±82.6	P 0.05




Fig. (1): Showing the correlation between serum leptin level and lumbar BMD between cases and controls. As regard T-score at lumbar spine (L2-L4); for the cases show was highly significant as shown in table (2). Estimation of serum leptin level for the cases with significant statistical difference between patients and controls as shown in table (3). Estimation of serum total cholesterol level for the cases significant statistical difference between patients and controls as shown in table (3). Estimation of serum LDL level for the cases with significant statistical difference between patients and controls as shown in table (3). Estimation of serum HDL level in our study for the cases with significant statistical difference between patients and controls as shown in table(3). Serum TG level was with mean for the osteoporotic patients, and) with mean(166±82.6) for controls with no significant statistical difference between patients and controls as shown in table(3)

## Discussion

Osteoporosis is a silent slowly progressive skeletal disease. It is characterized by low bone mass, deterioration of bone tissue and disruption of bone architecture, compromised bone strength and an increase in the risk of fracture. The risk for osteoporosis increases after menopause<sup>(11)</sup>

Osteoporosis is a major public health problem in Egypt. Constructed Bone mineral density charts for Egyptian women showed that, in general, they have a lower bone mineral density compared to their western counterparts **Sallam et al.**<sup>(12)</sup>. In our study we aimed to determine the association between BMD and circulating serum leptin levels among postmenopausal osteoporotic women. We found that leptin level was significantly lower among osteoporotic females. So higher serum leptin level is associated with higher BMD This result is in agreement with **Yamauchi et al.**<sup>(13)</sup> who had conducted his study to One

hundred and thirty-nine postmenopausal women (age 48-78 years, mean 62.5), who visited our outpatient clinic for the evaluation of osteoporosis, had reported that plasma leptin levels were positively correlated with BMD values, and multiple regression analysis revealed that this positive relationship was still observed with BMD values of the femoral neck and of the whole body, even after %fat and age were taken into account. Also **Thomas et al.**<sup>(14)</sup> who assessed the role of the candidate hormones, leptin, insulin, and estrogen in mediating fat mass effects on the skeleton in a sample of 137 premenopausal women (age range 21-54 years), 165 postmenopausal women (34-93 years), and 343 men (23-90 years) recruited from the general population, found that serum leptin correlated with BMD in women but not in men Another study done by **Pasco et al.**<sup>(15)</sup> found a significant positive association between the

BMD and serum leptin in women. **Cornish et al.**<sup>(16)</sup> found that leptin given peripherally increased bone strength in mice and also increased proliferation of osteoblasts in vitro. On the contrary, **Goulding et al.**<sup>(17)</sup> have not found any relationship between BMD, bone turnover markers and leptin concentration in postmenopausal women.

Also **Iwamoto**<sup>(18)</sup> found correlations between some skeletal sites and serum leptin, but not at the whole body, and the correlations with biochemical markers were weak. Aging is associated with changes in plasma levels of several hormones. There are several conflicting reports on leptin level changing during aging. In our study we found insignificant negative relation between age and leptin. This result is supported by **Ostlund**<sup>(19)</sup> who had found that circulating leptin is inversely related to age.

**Zhong et al.**<sup>(20)</sup> found that Serum leptin concentration was significantly higher in postmenopausal than premenopausal women ( $p < 0.001$ ).

In our study, positive correlation was found between leptin and BMI. **Douchi et al.**<sup>(21)</sup> had suggested that leptin may be a mediator between body fat and bone, because serum leptin levels correlates positively with fat mass in healthy subjects. However, **Pasco et al.**<sup>(22)</sup> found that the positive correlation between leptin and bone mass was independent of body weight. Literature concerning relationships between HDL cholesterol levels and BMD is contradictory. Our study found that lipid profile is moderately related to BMD. The level of serum total cholesterol and low density lipoprotein cholesterol were inversely associated BMD of lumbar spines (L2-L4).

Another study done by **Aleksandar et al.**<sup>(23)</sup> involved 300 women referred to densitometric examination as they belonged to the risk group of postmenopausal women, found that atherogenic lipoproteins negatively correlate with lumbar bone density. so Increase in values of cholesterol, LDL and triglyceride are connected with significant risk increase for the appearance of osteopenia or osteoporosis. Lumbar spine BMD was not associated with total cholesterol (TC), low density lipoprotein, cholesterol (LDL-C), and high density lipoprotein cholesterol (HDL-C) regardless of when the measurement was performed. In the current study, no significant correlation was found between TG and HDL and BMD lumbar spines (L2-L4). This result is consistent with the results of **Zabaglia et al. 1998**<sup>(24)</sup> who had

found no association between serum triglycerides and BMD in menopausal women. But, **Adami et al.**<sup>(25)</sup> had found that total body and hip BMD were positively related to serum triglycerides in women.

### Conclusion

The current study has provided evidence that bone mineral density is influenced by serum leptin level in postmenopausal women with statistically significant difference and positive correlation between serum leptin level and bone mineral density.

As regard total lipid profile, in our study inverse correlation between serum leptin level and total serum cholesterol and low density lipoprotein cholesterol levels.

### Recommendations

Serum leptin level measurement could be used as a simple and non invasive method for screening programs for osteoporosis in postmenopausal women.

### References :

1. **World Health Organization (2011):** Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of WHO study group. Geneva, Switzerland; WHO technical report series 843, WHO Fracture Risk Assessment Tool. Available at: <http://www.shef.ac.uk/FRAX>.
2. **Kanis JA (2007):** Assessment of Osteoporosis at the Primary Health Care Level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases. Sheffield, UK: University of Sheffield;100-131.vol 1
3. **Hamrick MW, Ferrari SL (2008):** "Leptin and the sympathetic connection of fat to bone". *Osteoporos Int.*, 19 (7): 905-912. doi:10.1007/s00198-007-0487-9.
4. **Jequier, E. (2002):** Pathways to obesity. *International journal of obesity and related metabolic. The spine journal : official journal of the North American Spine Society*, 6 (5): 479-87.
5. **Margetic S, Gazzola C, Pegg GG, Hill RA (2002):** "Leptin: a review of its peripheral actions and interactions". *Int. J. Obes. Relat. Metab. Disord.*, 26 (11): 1407-1433. doi:10.1038/sj.ijo.0802142. PMID 12439643.
6. **Malendowicz W, Rucinski M, Macchi C, Spinazzi R, Ziolkowska A, Nussdorfer GG, Kwias Z (2006):** "Leptin and leptin receptors in the prostate and seminal vesicles of the adult rat". *Int. J. Mol. Med.*, 18 (4): 615-8. PMID 16964413.
7. **Shoshana M Bartell, Srujana Rayalam, Suresh Ambati, Dhanunjaya R Gaddam, Diane L Hartzell (2012):** Central (ICV) leptin

- injection increases bone formation, bone vertebral fractures. *Osteoporos Int.*, 16:403–410.
8. **Adami S, Supronik J, Hala T (2006):** Effect of one year treatment with the cathepsin-K inhibitor, balicatib, on bone mineral density (BMD) in postmenopausal women with osteopenia/osteoporosis. *J Bone Miner Res.*, 21(1):s1-s530. Abstract 1085.
  9. **Manolagas S. C., S. Kousteni, and R. L. (2002):** Jilka, "Sex steroids and bone," *Recent Progress in Hormone Research*, 57: 385-409. View at Publisher. View at Google Scholar. View at Scopus.
  - 10 **Yun AJ and Lee PY.(2004):** Maldaptation of the link between inflammation and bone turnover may be a key determinant of osteoporosis. *Medical Hypotheses*, 63 (3):532-537.
  11. **Sambrook P (2008):** Osteoporosis Pathology and Pathophysiology. In: *Primer on the rheumatic diseases* by, Klippel J, Stone J, Crofford L and White P, eds., 13th ed., Springer, Newyork:584.
  12. **Sallam H, Galal A and Rashed A (2006):** Menopause in Egypt: past and present perspectives. *Climacteric*, 9,(6): 421-429.
  13. **Yamauchi M, Sugimoto T, Yamaguchi T, Nakaoka D, Kanzawa M, Yano S, Ozuru R, Sugishita T, Chihara K (2001):** Rlation between BMD and serum leptin. *Int. J. Clin. Paract*, Vol 4: pages 4: 341.
  14. **Thomas T, Burguera B, Melton LJ 3rd, Atkinson EJ, O'Fallon WM, Riggs BL, et al. (2000):** Relationship of serum leptin levels with body composition and sex steroid and insulin levels in men and women. *Metabolism*, 49: 1278-84.
  15. **Pasco JA, Henry MJ, Kotowicz MA, Sanders KM, Seeman E, Pasco JR, Schneider HG & Nicholson GC. (2004):** Seasonal periodicity of serum vitamin D and parathyroid hormone, bone resorption, and fractures: the Geelong Osteoporosis Study. *Journal of Bone and Mineral Research*, 19 :752-758.
  16. **Cornish, J.(2002):** Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. *J Endocrinol.*, 175: 405-15. Correlation between serum leptin levels and age, duration of postmenopausal period and body mass index.
  17. **Goulding A and Taylor RW. (1998):** Plasma leptin values in relation to bone mass and density and to dynamic biochemical markers of bone resorption and formation in postmenopausal women. *Calcif Tissue Int.*, 63: 456-458.
  18. **Iwamoto I, Douchi T, Kosha S, Murakami M, Fujino T & Nagata Y. (2000):** Relationships between serum leptin level and regional bone mineral density, bone metabolic markers in healthy women. *Acta Obstetricia et Gynecologica Scandinavica* ,79 :1060-1064.
  19. **Ostlund Jr RE, Yang JW, Klein S, Gingerich R. (1996):** Relation between plasma leptin concentration and body fat, gender, diet, age and metabolic covariates. Perceived psychological stress and serum leptin concentrations in Japanese men". *Obesity (Silver Spring)* ,14 (10): 1832–1838. doi:10.1038/oby.2006.211. PMID 17062814.
  20. Zhong N, Wu XP, Xu ZR, Wang AH, Luo XH, Cao XZ, Xie H, Shan PF, Liao EY (2005): Relationship of serum leptin with age, body weight, body mass index, and bone mineral density in healthy mainland Chinese women. Correlation of obesity and osteoporosis: effect of fat mass on the determination of osteoporosis. *J Bone Min Res.*, 23(1):17–29.
  21. **Yang WF, Tan GZ, Fu Z et al. (2009):** Evaluation of the diagnostic value of (18)F-FDG PET-CT and enhanced CT for staging of lymph node metastasis in non-small cell lung cancer. *Chinese Journal of Oncology*;31: 925–928.
  22. **Guglielmi G and Scalzo G. (2010):** Imaging tools transform diagnosis of osteoporosis. *Diagnostic Imaging Europe.*,26:7-11.
  23. **Aleksandar Dimic, Marina Rašić Popovic, Ivan Tasic, Dragan Djordjevic, Sonja Stojanovic,Bojana Stamenkovic, Dejan Popovic, Saša Milenkovic, Milena Dimic, and Jovan Nedovi (2012):** "Fructose-induced leptin resistance exacerbates weight gain in response to subsequent high-fat feeding". *American journal of physiology. Regulatory, integrative and comparative physiology*, 295 (5): R1370-R1375. doi:10.1152/ajpregu.00195.2008.
  24. **Zabaglia SF, Pedro AO, Pinto Neto AM,Sato M, Takeda N, Sarui H, Takami R, Takami K, Hayashi M, Sasaki A, Kawachi S, Yoshino K, Yasuda K (1998):** Association between serum leptin concentrations and bone mineral density, and biochemical markers of bone turnover in adult men.. 'Optimizing Bone Mass and Strength: The Role of Physical Activity and Nutrition during Growth. *Karger International Series in Medicine and Sport Science*, 51; 81-101.
  25. **Jeong IK, Cho SW, Kim SW, Choi HJ, Park KS, Kim SY, Lee HK, Cho SH, Oh BH, Shin CS.(2012):** Up-regulation of fetal rat lung parathyroid hormone-related protein gene regulatory network down-regulates the Sonic Hedgehog/Wnt/betacatenin gene regulatory network". *Pediatr. Res.*, 60 (4): 382-388. doi:10.1203/01.pdr.0000238326.42590.03. PMID 16940239.